Xeris Biopharma (NASDAQ:XERS) Hits New 1-Year High - Here's What Happened

Xeris Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Xeris Biopharma hit a new 52-week high, trading as high as $17.05 and last at $17.00, up from its prior close of $16.80.
  • Analyst views are mixed but lean positive: the stock has a “Moderate Buy” consensus and a $17 average price target, with four Buy, one Hold, and one Sell rating.
  • The company beat quarterly expectations, reporting EPS of $0.06 versus $0.03 forecast and revenue of $107.23 million versus $101.68 million expected.
  • Five stocks to consider instead of Xeris Biopharma.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s share price hit a new 52-week high on Wednesday. The company traded as high as $17.05 and last traded at $17.00, with a volume of 143,390 shares. The stock had previously closed at $16.80.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on XERS. Weiss Ratings reissued a "sell (d-)" rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Barclays upped their price objective on Xeris Biopharma from $14.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 11th. Wall Street Zen raised Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 7th. Leerink Partners increased their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research report on Thursday, September 10th. Finally, HC Wainwright raised their target price on Xeris Biopharma from $10.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, November 6th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $17.00.

View Our Latest Analysis on XERS

Xeris Biopharma Stock Up 2.4%

The firm's 50 day simple moving average is $10.73 and its 200 day simple moving average is $7.93. The company has a market cap of $3.14 billion, a price-to-earnings ratio of -343.21 and a beta of 0.61. The company has a quick ratio of 1.58, a current ratio of 2.15 and a debt-to-equity ratio of 3.89.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. The business had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Beth Hecht sold 25,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the transaction, the insider owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $51,150.00. Following the transaction, the insider owned 1,346,053 shares in the company, valued at $13,770,122.19. This represents a 0.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 168,332 shares of company stock valued at $1,678,971 in the last quarter. Corporate insiders own 4.35% of the company's stock.

Institutional Trading of Xeris Biopharma

Institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Xeris Biopharma during the 2nd quarter worth approximately $115,042,000. Legal & General Group Plc purchased a new stake in shares of Xeris Biopharma in the second quarter valued at $15,941,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Xeris Biopharma in the second quarter valued at $14,316,000. Bank of America Corp DE purchased a new stake in shares of Xeris Biopharma in the second quarter valued at $11,065,000. Finally, Vilga Financial Planning LLC purchased a new stake in shares of Xeris Biopharma in the third quarter valued at $10,134,000. Institutional investors and hedge funds own 42.75% of the company's stock.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Xeris Biopharma Right Now?

Before you consider Xeris Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.

While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines